Pheochromocytoma Market Report 2026

Pheochromocytoma Market Overview

• Pheochromocytoma market size has reached to $3.13 billion in 2025 • Expected to grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 4.6% • Growth Driver: Rising Tumor Incidence Rates Fueling Growth In The Pheochromocytoma Market • Market Trend: Innovative Clinical Trials Drive Advancements In Pheochromocytoma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pheochromocytoma Market?

Pheochromocytoma is a rare tumor that forms in the center of one or both adrenal glands. These tumors arise from the adrenal medulla cells, which are responsible for producing hormones such as adrenaline (epinephrine) and noradrenaline (norepinephrine). Pheochromocytomas can lead to excessive secretion of these hormones, causing symptoms like high blood pressure, rapid heartbeat, anxiety and related effects. The main types of pheochromocytomas are adrenal pheochromocytomas and extra-adrenal pheochromocytomas. Adrenal pheochromocytoma refers to a specific type of pheochromocytoma that originates in the adrenal glands, which are located on top of the kidneys and can lead to the excessive production of hormones like adrenaline and noradrenaline, causing symptoms such as high blood pressure and a rapid heart rate. The treatment for pheochromocytoma includes medication, surgery, radionuclide treatment and others, as well as laboratory tests, imaging tests and genetic testing, which are integrated for the diagnosis of pheochromocytoma and provided by end users such as hospitals, clinics, research and academic institutes and others.

What Is The Pheochromocytoma Market Growth Forecast?

The pheochromocytoma market size is expected to see steady growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing adoption of precision oncology approaches, rising investments in rare tumor research, expansion of genetic screening programs, increasing use of targeted therapies, advancements in radionuclide treatment techniques. Major trends in the forecast period include increasing adoption of advanced imaging diagnostics, rising use of genetic testing for tumor identification, growing preference for minimally invasive surgical treatments, expansion of targeted radionuclide therapies, enhanced focus on early disease detection.

Global Pheochromocytoma Market Segmentation

1) By Type: Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma 2) By Treatment: Medication, Surgery, Radionuclide Treatment, Other Treatments 3) By Diagnosis: Laboratory Tests, Imaging Tests, Genetic Testing 4) By End Users: Hospitals, Clinics, Research And Academic Institutes, Other End Users Subsegments: 1) By Adrenal Pheochromocytoma: Unilateral Adrenal Pheochromocytoma, Bilateral Adrenal Pheochromocytoma 2) By Extra-Adrenal Pheochromocytoma: Sympathetic Paraganglioma, Parasympathetic Paraganglioma

What Is The Driver Of The Pheochromocytoma Market?

The growing incidence rate of tumors is expected to propel the growth of the pheochromocytoma market going forward. Tumors are abnormal growths of cells that can be benign (non-cancerous) or malignant (cancerous). The rising cases of tumors and cancers emphasize the need for growing medical awareness, accurate diagnosis, and tailored treatment strategies for managing desmoid pheochromocytoma effectively. Pheochromocytoma, a rare tumor of the adrenal glands, contributes to the growing incidence rate of tumors by adding to the overall number of diagnosed endocrine neoplasms, as improved detection and awareness lead to more cases being identified. For instance, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023. Therefore, the growing incidence rate of tumors will drive the growth of the pheochromocytoma industry going forward.

Key Players In The Global Pheochromocytoma Market

Major companies operating in the pheochromocytoma market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International plc, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE

Global Pheochromocytoma Market Trends and Insights

Major companies operating in the pheochromocytoma market are conducting clinical trials to test new treatment approaches, therapies, and medications for pheochromocytoma, leading to the development of more effective and targeted treatments and improving patient outcomes. For instance, in May 2025, Merck & Co., a US-based biopharmaceutical company, received Food and Drug Administration (FDA) approval for Welireg (belzutifan), an oral therapy for adults and pediatric patients (≥ 12 years) with locally advanced pheochromocytoma or paraganglioma (PPGL), and this treatment targets tumor growth by selectively inhibiting hypoxia-inducible factor 2 alpha (HIF 2α), a key molecular driver in many PPGL tumors, helping to reduce tumor progression. Additionally, Welireg is designed as a convenient oral therapy, providing a targeted, non-surgical option for long-term management of advanced pheochromocytoma and paraganglioma (PPGL) in eligible patients.

What Are Latest Mergers And Acquisitions In The Pheochromocytoma Market?

In August 2024, Laboratory Corporation, a US-based healthcare corporation that provides laboratory services to help improve health and lives, acquired assets of Invitae Corporation for an undisclosed amount. Laboratory Corporation aims to enhance its genetic testing capabilities, improve patient care through advanced diagnostics, and expand its revenue streams in specialty testing. Invitae Corporation is a US-based medical genetics company that offers genetic testing to help identify hereditary syndromes associated with pheochromocytoma.

Regional Outlook

North America was the largest region in the pheochromocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pheochromocytoma Market?

The pheochromocytoma market consists of revenues earned by entities by providing ablation therapy, embolization therapy and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pheochromocytoma market also includes sales of prazosin, terazosin and doxazosin, which are used in providing pheochromocytoma treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pheochromocytoma Market Report 2026?

The pheochromocytoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pheochromocytoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.